Law360, New York (July 02, 2010, 1:35 PM ET) -- Actavis Pharma Manufacturing Pvt. Ltd. LLC and Sandoz Inc. have fired back at Novo Nordisk Inc.'s bid to block them from producing generic versions of diabetes treatment Prandin, alleging that Novo obtained the asserted patent for the drug through inequitable conduct.
The generics makers lodged their counterclaims in two related infringement suits in the U.S. District Court for the Southern District of New York on Thursday, claiming Novo concealed clinical trial reports from patent examiners and provided the U.S. Food and Drug Administration with materially inaccurate...
Actavis, Sandoz Open Fire On Prandin Patent
To view the full article, take a free trial now.
